NCT06558461

Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis

Evaluating the Efficacy of Nebulised 3% Hypertonic Saline for Acute Bronchiolitis in Infants: A Study at Can Tho Children's Hospital, 2022-2024

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Can Tho University of Medicine and Pharmacy · Academic / Other
• Sex: All
• Age: 1 Month – 24 Months
• Healthy volunteers: Not accepted

Summary

This study aims to determine the efficacy of nebulising 3% hypertonic saline in improving clinical symptoms and reducing the length of hospital stay in infants with acute bronchiolitis.

Detailed description

Bronchiolitis is the most prevalent disease in infants, especially children younger than two years old. Clinical manifestations vary from mild to severe, even life-threatening respiratory failure. Airway oedema and mucus plugging are the principal pathological features in infants with acute bronchiolitis. Nebulising 3% hypertonic saline solution may reduce these pathological changes, but the evidence remains equivocal.

Conditions

• Acute Bronchiolitis

Interventions

Type	Name	Description
DRUG	3% Sodium Chloride	4ml nebulized three times daily
OTHER	Standard care	Standard care

Timeline

• Start date: 2022-06-01
• Primary completion: 2024-05-27
• Completion: 2024-05-28
• First posted: 2024-08-16
• Last updated: 2024-08-16

Locations

1 site across 1 country: Vietnam

Regulatory

• FDA-regulated drug study